SUSMED,Inc. (JP:4263)
:4263
Want to see JP:4263 full AI Analyst Report?
4263 Stock Chart & Stats
¥821.00
¥24.00(3.84%)
At close: 4:00 PM EST
¥821.00
¥24.00(3.84%)
Day’s Range― - ―
52-Week Range¥518.00 - ¥1,231.00
Previous CloseN/A
Volume269.90K
Average Volume (3M)121.17K
Market Cap
¥16.06B
Enterprise Value¥12.14B
Total Cash (Recent Filing)¥4.40B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio2.02
Price to Book (P/B)2.35
Price to Sales (P/S)22.16
P/FCF Ratio-23.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSUSMED’s ~97% gross margins indicate exceptionally strong unit economics in its digital-health offerings. This structural margin cushion supports scalability and long-term profitability potential if operating expenses are reined in, enabling leverage as revenue grows.
Debt-Free Balance SheetA debt-free balance sheet with substantial equity reduces solvency risk and gives management optionality to fund R&D or operations without immediate refinancing. This structural financial flexibility lengthens runway and lowers default risk during scale-up.
Revenue Growth ResumptionRevenue recovery in 2025 shows renewed commercial traction after prior declines, suggesting product-market fit improvements. Sustained top-line growth provides the platform to spread fixed costs, improve operating leverage, and move toward durable profitability over time.
Bears Say
Deep Ongoing LossesPersistent, large net losses indicate the company’s operating model has not yet converted strong unit economics into positive overall profits. Continued negative margins erode equity, require external funding over time, and reflect structural cost or scale challenges to delivering investor returns.
Worsening Cash BurnOperating and free cash flow turned negative and worsened in 2025, signaling accelerating cash burn. This structural cash deficit raises financing needs, risks dilution or constrained investment, and limits the firm’s ability to sustain growth without improving operating cash conversion.
Negative Returns On EquityNegative ROE means capital deployed is not generating shareholder returns and equity has declined 2023–2025. Structurally, this highlights an inability to convert assets and investment into profitable growth, challenging long-term value creation unless performance reverses.
4263 FAQ
What was SUSMED,Inc.’s price range in the past 12 months?
SUSMED,Inc. lowest stock price was ¥518.00 and its highest was ¥1231.00 in the past 12 months.
What is SUSMED,Inc.’s market cap?
SUSMED,Inc.’s market cap is ¥16.06B.
When is SUSMED,Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SUSMED,Inc.’s earnings last quarter?
Currently, no data Available
Is SUSMED,Inc. overvalued?
According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued.
Does SUSMED,Inc. pay dividends?
SUSMED,Inc. does not currently pay dividends.
What is SUSMED,Inc.’s EPS estimate?
SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SUSMED,Inc. have?
SUSMED,Inc. has 16,868,100 shares outstanding.
What happened to SUSMED,Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SUSMED,Inc.?
Currently, no hedge funds are holding shares in JP:4263
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SUSMED,Inc.
SUSMED, Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. The company also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, it offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.